Drug intelligence / Profile preview

ceftazidime + netilmicin + teicoplanin

Development stage: Unknown
Lead developer: GSK
Modality: Small Molecules
Administration: Intravenous, Intramuscular

Overview

A combination antibiotic regimen consisting of ceftazidime (a third-generation cephalosporin), netilmicin (an aminoglycoside), and teicoplanin (a glycopeptide antibiotic). This combination provides broad-spectrum coverage against both Gram-negative and Gram-positive bacteria and is primarily used for empiric therapy in febrile neutropenic patients, particularly those who have undergone bone marrow transplantation. The regimen is especially valuable for patients not responding to initial beta-lactam and aminoglycoside therapy alone.

Targets

Bacterial RibosomePBP (Penicillin-binding protein family)D-Ala-D-Ala (D-Ala-D-Ala terminus)

Beyond the preview

Go deeper on ceftazidime + netilmicin + teicoplanin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ceftazidime + netilmicin + teicoplanin.

Explore the full profile